FibroBiologics, Inc.
FBLG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001958777
No open-market purchases or sales by FibroBiologics, Inc. insiders were filed in the last 90 days; 16 institutions reported holding it in 13F filings for Q2 2026, worth $269.6K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in FibroBiologics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −1 vs. Q1 2026
- Shares held
- 284.9K
- +64.3K (+29.1%) vs. Q1 2026
- Total value
- $269.6K
- −$21.4K (−7.4%) vs. Q1 2026
- New holders
- 3
- 5 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FBLG on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 16 | $269.6K |
| Q1 2026 | 17 | $291.1K |
| Q4 2025 | 46 | $993.8K |
| Q3 2025 | 55 | $2.93M |
| Q2 2025 | 59 | $3.75M |
| Q1 2025 | 65 | $5.81M |
| Q4 2024 | 64 | $11.9M |
| Q3 2024 | 61 | $16.8M |
| Q2 2024 | 50 | $17.2M |
| Q1 2024 | 17 | $5.18M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding FibroBiologics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Allworth Financial LP | 13 | $13 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 64 | $61 | 0.00% | −2−3.0% | Reduced |
| Grove Bank & Trust | 100 | $95 | 0.00% | +100 | New |
| Islay Capital Management, LLC | 169 | $160 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 1,522 | $1.00K | 0.00% | +1,336+718.3% | Added |
| UBS Group AG | 1,073 | $1.02K | 0.00% | −4,648−81.2% | Reduced |
| Advisor Group Holdings, Inc. | 2,404 | $2.28K | 0.00% | +2,250+1,461.0% | Added |
| Tower Research Capital LLC (TRC) | 4,728 | $4.48K | 0.00% | +4,268+927.8% | Added |
| Vanguard Fiduciary Trust Co | 6,380 | $6.05K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 7,243 | $6.86K | 0.00% | +7,243 | New |
| BlackRock, Inc. | 18,238 | $17.3K | 0.00% | −6,409−26.0% | Reduced |
| Qube Research & Technologies Ltd | 24,313 | $23.0K | 0.00% | +24,313 | New |
| Vanguard Capital Management LLC | 27,769 | $26.3K | 0.00% | −39,896−59.0% | Reduced |
| Geode Capital Management, LLC | 30,299 | $28.7K | 0.00% | +690+2.3% | Added |
| Fund Evaluation Group, LLC | 51,794 | $49.1K | 0.00% | 00.0% | Unchanged |
| Cascade Financial Partners, LLC | 108,828 | $103.1K | 0.01% | +92,400+562.5% | Added |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −15,997−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −845−100.0% | Sold out |
| Vanguard Global Advisers, LLC | 0 | $0 | 0.00% | −536−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −10−100.0% | Sold out |